铁调素在低危骨髓增生异常综合征中的研究进展  

Progress of hepcidin in low-risk myelodysplastic syndromes

作　　者：郑秦 罗梅宏[1] Zheng Qin;Luo Meihong(Department of Hematology,Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine,Baoshan Branch of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201900,China)

机构地区：[1]上海中医药大学附属曙光医院宝山分院上海市宝山区中西医结合医院血液科,201900

出　　处：《白血病．淋巴瘤》2020年第7期439-441,共3页Journal of Leukemia & Lymphoma

基　　金：上海市卫生与计划生育委员会科研项目(20184Y0094);上海市卫生与计划生育委员会三年行动计划-优势病种培育项目(ZY(2018-2020)-ZYBZ-32)。

摘　　要：无效造血、炎症和铁过载共同参与骨髓增生异常综合征(MDS)铁代谢的调节,不同类型的MDS在不同阶段呈现着不同的铁状态,铁调素在其中发挥关键作用。目前研究已证明铁代谢异常是影响低危MDS患者预后的独立危险因素。文章总结了铁调素在低危MDS中的研究进展,并进一步探讨铁调素在低危MDS患者的治疗前景。Ineffective hematopoiesis,inflammation and iron overload are involved in the regulation of iron metabolism in myelodysplastic syndromes(MDS).Different types of MDS present different iron states at different stages,hepcidin play a key role in it.Current studies have demonstrated that iron metabolism abnormality is an independent risk factor for the prognosis of low-risk MDS.This article summarizes the research progress of hepcidin in patients with low-risk MDS and further explores the therapeutic prospects of hepcidin in patients with low-risk MDS.

关 键 词：骨髓增生异常综合征 铁调素 

分 类 号：R551.3[医药卫生—血液循环系统疾病]